JP2024540839A5 - - Google Patents

Info

Publication number
JP2024540839A5
JP2024540839A5 JP2024520702A JP2024520702A JP2024540839A5 JP 2024540839 A5 JP2024540839 A5 JP 2024540839A5 JP 2024520702 A JP2024520702 A JP 2024520702A JP 2024520702 A JP2024520702 A JP 2024520702A JP 2024540839 A5 JP2024540839 A5 JP 2024540839A5
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutical composition
alkyl
kras
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540839A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/045623 external-priority patent/WO2023059598A1/en
Publication of JP2024540839A publication Critical patent/JP2024540839A/ja
Publication of JP2024540839A5 publication Critical patent/JP2024540839A5/ja
Pending legal-status Critical Current

Links

JP2024520702A 2021-10-05 2022-10-04 Kras g12d阻害剤とshp-2阻害剤との併用療法 Pending JP2024540839A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252561P 2021-10-05 2021-10-05
US63/252,561 2021-10-05
PCT/US2022/045623 WO2023059598A1 (en) 2021-10-05 2022-10-04 Combination therapies of kras g12d inhibitors with shp-2 inhibitors

Publications (2)

Publication Number Publication Date
JP2024540839A JP2024540839A (ja) 2024-11-06
JP2024540839A5 true JP2024540839A5 (cg-RX-API-DMAC7.html) 2025-10-10

Family

ID=85803689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520702A Pending JP2024540839A (ja) 2021-10-05 2022-10-04 Kras g12d阻害剤とshp-2阻害剤との併用療法

Country Status (6)

Country Link
US (1) US20240423984A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412719A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540839A (cg-RX-API-DMAC7.html)
KR (1) KR20240073114A (cg-RX-API-DMAC7.html)
CN (1) CN118401254A (cg-RX-API-DMAC7.html)
WO (1) WO2023059598A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
US20260200925A1 (en) * 2021-11-24 2026-07-16 Merck Sharp & Dohme Llc Small molecule inhibitors of kras mutated proteins
EP4531846A4 (en) * 2022-06-03 2026-05-27 Verastem Inc POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
WO2024012456A1 (zh) * 2022-07-12 2024-01-18 南京明德新药研发有限公司 哌嗪桥取代的杂环并嘧啶类化合物
KR20260074651A (ko) * 2023-08-22 2026-05-26 사노피 암의 치료를 위한 kras g12d 억제제로서의 2-(3,8-디아자비시클로[3.2.1]옥탄-3-일)-1,3,5-트리아진 유도체
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2026080796A1 (en) * 2024-10-11 2026-04-16 Mirati Therapeutics, Inc. Mrtx1133 capsule pharmaceutical compositions
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) * 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
US20240139193A1 (en) 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2022076917A1 (en) * 2020-10-08 2022-04-14 Kumquat Biosciences Inc. Modulators of cell proliferation and uses thereof
US20240166669A1 (en) 2021-03-05 2024-05-23 Nikang Therapeutics, Inc. Quinazoline amine derivatives as kras inhibitors
WO2023284730A1 (en) 2021-07-14 2023-01-19 Nikang Therapeutics, Inc. Alkylidene derivatives as kras inhibitors

Similar Documents

Publication Publication Date Title
JP2024537140A5 (cg-RX-API-DMAC7.html)
JP2024537136A5 (cg-RX-API-DMAC7.html)
JP2022548791A5 (cg-RX-API-DMAC7.html)
JP2022500381A5 (cg-RX-API-DMAC7.html)
JP2024537139A5 (cg-RX-API-DMAC7.html)
JP2025000632A5 (cg-RX-API-DMAC7.html)
JP2022500385A5 (cg-RX-API-DMAC7.html)
JP2022500388A5 (cg-RX-API-DMAC7.html)
JP2022500384A5 (cg-RX-API-DMAC7.html)
JP2025000629A5 (cg-RX-API-DMAC7.html)
JP2024537137A5 (cg-RX-API-DMAC7.html)
JP2022530866A5 (cg-RX-API-DMAC7.html)
US9643977B2 (en) Necroptosis inhibitors and methods of use therefor
JP2022535577A5 (cg-RX-API-DMAC7.html)
FI3849537T3 (fi) Yhdistelmäterapioita
JP2019516718A5 (cg-RX-API-DMAC7.html)
JP2004528379A5 (cg-RX-API-DMAC7.html)
JP2010536842A5 (cg-RX-API-DMAC7.html)
EA007933B1 (ru) 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность
JP2008500992A5 (cg-RX-API-DMAC7.html)
JP2010515715A5 (cg-RX-API-DMAC7.html)
JP2013512903A5 (cg-RX-API-DMAC7.html)
CA2551737A1 (en) Helix 12 directed steroidal pharmaceutical products
JP2014521653A5 (cg-RX-API-DMAC7.html)
JP2013538196A (ja) 2−置換−8−アルキル−7−オキソ−7,8−ジヒドロピリド[2,3d]ピリミジン−6−カルボニトリル及びその使用